Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used routinely on the NHS in England and Wales for the first-line treatment of untreated, advanced, unresectable hepatocellular carcinoma (HCC).
Specifically, the recommendation allows the drug to be used in adult liver cancer patients with Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
